why choose us

First received: December 13, 2022

Clinical Trial: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hematologic Diseases

Study Type: INTERVENTIONAL


Official Title: A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability,

Brief Summary: This will be a first time in human (FTIH) study in sickle cell diseases (SCD) participants.The FTIH study is planned to evaluate the safety, tolerability, and pharmacokinetics of GSK4172239D.The study will be composed of 3 periods for all participants (Screening, Treatment, and Follow up).Participants will be screened and, prior to first dose on Day 1, will be randomized to receive either GSK4172239D or placebo.GSK4172239D is a prodrug that is converted in vivo into GSK4106401.This study will be a single dose,…

Read more